Lyra Therapeutics, Inc. (LYRA) Financials

LYRA Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 120.6 million 36.3 million
2023-06-30 125.7 million 27.1 million
2023-03-31 93.9 million 27.8 million
2022-12-31 110.0 million 29.2 million

LYRA Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -14.3 million 1.4 million
2023-06-30 -14.4 million 1.4 million
2023-03-31 -15.9 million 1.6 million
2022-12-31 -12.2 million 1.8 million

LYRA Net Income

No data available :(

LYRA Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 102.6 million - 6.3 million
2023-06-30 116.2 million - 1.7 million
2023-03-31 82.7 million - 2.1 million
2022-12-31 97.9 million - 2.2 million

LYRA Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 57.0 million
2023-06-30 43.7 million
2023-03-31 36.8 million
2022-12-31 30.2 million

LYRA Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 144000 12.4 million 5.0 million -
2023-06-30 71000 10.8 million 4.6 million -
2023-03-31 45000 12.6 million 5.1 million -
2022-12-31 28000 9.5 million 4.4 million -

LYRA Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 544000 12.4 million
2023-06-30 458000 10.8 million
2023-03-31 410000 284000
2022-12-31 11000 222000

LYRA

Price: $4.03

52 week price:
1.93
6.79

Earnings Per Share: -1.26 USD

P/E Ratio: -3.34

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 10913

Market Capitalization: 299.9 million

Links: